Intercept's latest NASH setback to be the last

23 June 2023

Nobody can say that US biopharma Intercept Pharmaceuticals (Nasdaq: ICPT) has not done all it can to reach market with a long-awaited treatment for non-alcoholic steatohepatitis (NASH).

But the company’s latest setback has led management to accept that it is finally the end of the road, with a restructuring and new focus away from NASH announced on Friday.

"We are taking decisive actions that we believe will improve our ability to drive long-term growth and maintain leadership with our PBC business"This follows this week’s US Food and Drug Administration (FDA) fresh rejection of obeticholic acid (OCA) in pre-cirrhotic liver fibrosis due to NASH.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK